PL2069334T3 - Aspalatyno-podobny dihydrochalkon, wyciągi z niefermentowanego czerwonokrzewu i sposób wytwarzania - Google Patents

Aspalatyno-podobny dihydrochalkon, wyciągi z niefermentowanego czerwonokrzewu i sposób wytwarzania

Info

Publication number
PL2069334T3
PL2069334T3 PL08801873T PL08801873T PL2069334T3 PL 2069334 T3 PL2069334 T3 PL 2069334T3 PL 08801873 T PL08801873 T PL 08801873T PL 08801873 T PL08801873 T PL 08801873T PL 2069334 T3 PL2069334 T3 PL 2069334T3
Authority
PL
Poland
Prior art keywords
preparation
aspalathin
dihydrochalcone
extracts
trihydroxy
Prior art date
Application number
PL08801873T
Other languages
English (en)
Other versions
PL2069334T5 (pl
Inventor
Bruno Frank
Wilfried Dimpfel
Original Assignee
Kneipp Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38805677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2069334(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kneipp Gmbh filed Critical Kneipp Gmbh
Publication of PL2069334T3 publication Critical patent/PL2069334T3/pl
Publication of PL2069334T5 publication Critical patent/PL2069334T5/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08801873T 2007-10-23 2008-09-05 Aspalatyno-podobny dihydrochalkon, wyciągi z niefermentowanego czerwonokrzewu i sposób wytwarzania PL2069334T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07020728A EP2053050B1 (de) 2007-10-23 2007-10-23 Aspalathin-ähnliches Dihydrochalcon und Verfahren zur Herstellung
PCT/EP2008/007279 WO2009052895A1 (de) 2007-10-23 2008-09-05 Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung
EP08801873.4A EP2069334B2 (de) 2007-10-23 2008-09-05 Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung

Publications (2)

Publication Number Publication Date
PL2069334T3 true PL2069334T3 (pl) 2012-04-30
PL2069334T5 PL2069334T5 (pl) 2015-06-30

Family

ID=38805677

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07020728T PL2053050T3 (pl) 2007-10-23 2007-10-23 Podobny do aspalatyny dihydrochalkon i sposób jego wytwarzania
PL08801873T PL2069334T5 (pl) 2007-10-23 2008-09-05 Aspalatyno-podobny dihydrochalkon, wyciągi z niefermentowanego czerwonokrzewu i sposób wytwarzania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07020728T PL2053050T3 (pl) 2007-10-23 2007-10-23 Podobny do aspalatyny dihydrochalkon i sposób jego wytwarzania

Country Status (10)

Country Link
US (1) US20100222423A1 (pl)
EP (2) EP2053050B1 (pl)
JP (1) JP5527900B2 (pl)
AT (2) ATE522524T1 (pl)
DK (2) DK2053050T3 (pl)
ES (2) ES2372203T3 (pl)
HR (1) HRP20110890T4 (pl)
PL (2) PL2053050T3 (pl)
PT (2) PT2053050E (pl)
WO (1) WO2009052895A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
JP6797408B2 (ja) 2014-11-06 2020-12-09 国立大学法人 長崎大学 新規アルツハイマー病治療薬
JP6735224B2 (ja) * 2016-01-28 2020-08-05 花王株式会社 アストロサイトのグルコース代謝活性化剤
JP7244273B2 (ja) * 2018-12-27 2023-03-22 株式会社 伊藤園 ルイボス茶飲料の製造方法
CN109932448A (zh) * 2019-03-29 2019-06-25 完美(广东)日用品有限公司 一种线叶金雀花及其制品中有效成分的含量测定方法
CN115104730A (zh) * 2022-06-28 2022-09-27 北京姿美堂生物技术股份有限公司 一种改善睡眠的组合物、线叶金雀花-芦笋睡眠改善液、茶粉的制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2895298B2 (ja) * 1991-12-27 1999-05-24 株式会社ユニエ 活性酸素消去・除去剤
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
JPH11116429A (ja) 1997-10-13 1999-04-27 Mikimoto Pharmaceut Co Ltd 化粧品原料および化粧品
JP2001316239A (ja) * 2000-05-10 2001-11-13 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
KR100421233B1 (ko) * 2001-09-10 2004-03-11 한국원자력연구소 식품, 의약품 및 화장품 제조용 천연물의 색도 개선 방법 및 이의 방법에 의해 색도가 개선된 천연물 추출물
ZA200303674B (en) * 2002-02-20 2005-04-26 Benedict Technology Holdings P Antioxidant composition.
JP4637491B2 (ja) * 2004-03-01 2011-02-23 株式会社東洋発酵 抗アレルギー用組成物
DE102004052800B4 (de) * 2004-10-30 2017-02-23 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Verbesserte Trägerformulierungen
DE102005004438B4 (de) * 2005-01-31 2007-12-20 Raps Gmbh & Co. Kg Rooibos-Extrakt mit erhöhtem Aspalathingehalt, Verfahren zur Herstellung eines solchen Rooibos-Extraktes und kosmetisches Mittel enthaltend einen solchen Rooibos-Extrakt
JP2007161661A (ja) * 2005-12-15 2007-06-28 Pola Chem Ind Inc アドバンスド・グリケーション・エンドプロダクツを分解するための化粧料とその製造法
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.

Also Published As

Publication number Publication date
HRP20110890T4 (en) 2015-02-27
ATE533763T1 (de) 2011-12-15
EP2053050B1 (de) 2011-08-31
ES2372203T3 (es) 2012-01-17
JP2011501755A (ja) 2011-01-13
HRP20110890T1 (hr) 2011-12-31
DK2053050T3 (da) 2011-11-21
PT2053050E (pt) 2011-12-09
EP2069334A1 (de) 2009-06-17
DK2069334T4 (da) 2014-12-08
ES2373509T5 (es) 2015-02-16
ATE522524T1 (de) 2011-09-15
JP5527900B2 (ja) 2014-06-25
PL2069334T5 (pl) 2015-06-30
EP2069334B1 (de) 2011-11-16
EP2069334B2 (de) 2014-11-05
PT2069334E (pt) 2011-12-30
DK2069334T3 (da) 2012-01-23
ES2373509T3 (es) 2012-02-06
US20100222423A1 (en) 2010-09-02
PL2053050T3 (pl) 2012-01-31
EP2053050A1 (de) 2009-04-29
WO2009052895A1 (de) 2009-04-30

Similar Documents

Publication Publication Date Title
HRP20110890T4 (en) Aspalathin-like dihydrochalcone, extracts from unfermented rooibos and process for preparation
EG25488A (en) Fungicidal mixtures of thiophene derivative
NZ594739A (en) Solid pharmaceutical composition comprising amlodipine and losartan
MX2007013623A (es) Preparacion externa para la piel.
EP2178869A4 (en) INDOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS
WO2008027542A3 (en) 5-substituted isoindoline compounds
WO2009047723A3 (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
IL205974A (en) 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound
WO2009058798A3 (en) Orally disintegrated dosage form
EP1994928A8 (en) Antimicrobial agent and antimicrobial composition
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2010087565A3 (ko) 피페린의 신규한 용도
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2008020314A3 (en) Statin stabilizing dosage formulations
PE20020351A1 (es) Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
WO2010013925A3 (en) Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
WO2008022745A8 (de) Formulierungen zur kontrollierten freisetzung agrochemischer wirkstoffe
WO2009038411A3 (en) Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety
WO2009108017A3 (en) New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
WO2011075799A3 (en) Oral antidepressant formulation